Taro Semba Selected Research

N- (3- cyano- 4- methyl- 1H- indol- 7- yl)- 3- cyanobenzene- sulfonamide

8/2014	Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
2/2004	An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker.
11/2002	Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taro Semba Research Topics

Disease

11	Neoplasms (Cancer) 12/2022 - 11/2002
3	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2014
2	Hypoxia (Hypoxemia) 01/2021 - 10/2014
1	Febrile Neutropenia 01/2022
1	Triple Negative Breast Neoplasms 01/2022
1	Neutropenia 01/2022
1	Stomach Neoplasms (Stomach Cancer) 01/2021
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2021
1	Polyps 01/2021
1	Sarcoma (Soft Tissue Sarcoma) 01/2016
1	Neoplasm Metastasis (Metastasis) 10/2014
1	Vascular Remodeling 10/2014
1	Lung Neoplasms (Lung Cancer) 08/2014
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2014
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2014
1	Colorectal Neoplasms (Colorectal Cancer) 11/2002

Drug/Important Bio-Agent (IBA)

5	eribulin FDA Link 01/2022 - 10/2014
3	N- (3- cyano- 4- methyl- 1H- indol- 7- yl)- 3- cyanobenzene- sulfonamideIBA 08/2014 - 11/2002
2	ErbB Receptors (EGF Receptor)IBA 01/2022 - 08/2014
2	Capecitabine (Xeloda)FDA Link 12/2020 - 10/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2014 - 01/2014
2	lenvatinibIBA 06/2014 - 01/2014
2	Angiogenesis InhibitorsIBA 01/2014 - 02/2004
2	Biomarkers (Surrogate Marker)IBA 01/2014 - 02/2004
1	Hormones (Hormone)IBA 01/2022
1	pegfilgrastim (Neulasta)FDA Link 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	CateninsIBA 01/2021
1	CREB-Binding ProteinIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Fulvestrant (Faslodex)FDA Link 12/2020
1	palbociclibIBA 12/2020
1	Cadherins (E-Cadherin)IBA 12/2020
1	Phenobarbital (Luminal)FDA Link 12/2020
1	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 10/2014
1	TubulinIBA 10/2014
1	Proteins (Proteins, Gene)FDA Link 10/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2014
1	Tyrosine Kinase InhibitorsIBA 08/2014
1	Conditioned Culture MediaIBA 06/2014
1	N- (2- fluoro- 4- ((2- (4- (4- methylpiperazin- 1- yl)piperidin- 1- yl)carbonylaminopyridin- 4- yl)oxy)phenyl)- N'- (4- fluorophenyl)cyclopropane- 1,1- dicarboxamideIBA 06/2014
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2014
1	Integrin alpha2IBA 02/2004
1	matrigelIBA 02/2004
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 02/2004

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2014
2	Oral Administration 02/2004 - 11/2002
1	Aftercare (After-Treatment) 12/2022
1	Drug Therapy (Chemotherapy) 12/2020